Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

User Fees Should Recognize Complete Product Life Cycle - FDA's Feigal

This article was originally published in The Tan Sheet

Executive Summary

The design of FDA's user fee system should encourage attention to the entire life cycle of a product, Center for Devices & Radiologic Health Director David Feigal, MD, said at the Food & Drug Law Institute meeting in Washington, D.C. June 5.

You may also be interested in...



FDA Wants More "Predictable" Revenue Stream Under PDUFA III

FDA would like to ensure a more "predictable" revenue stream under the third Prescription Drug User Fee Act.

FDA Wants More "Predictable" Revenue Stream Under PDUFA III

FDA would like to ensure a more "predictable" revenue stream under the third Prescription Drug User Fee Act.

FDA Wants More "Predictable" Revenue Stream Under PDUFA III

FDA would like to ensure a more "predictable" revenue stream under the third Prescription Drug User Fee Act.

Related Content

Topics

UsernamePublicRestriction

Register

PS091315

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel